Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. (AIM) announced the commencement of patient enrollment in a Phase 2 clinical trial funded by the National Cancer Institute. The trial evaluates the combination of a type-1 polarized dendritic cell vaccine with Interferon alpha-2b, Ampligen, and Celecoxib for HLA-A2+ refractory melanoma patients. First patient dosing is expected in Q4 2022. The study aims to enroll up to 24 participants, assessing objective response rates and efficacy. AIM's CEO views this as a significant milestone in developing second-line therapies for patients resistant to PD-1/PD-L1 treatment.

AIM ImmunoTech (NYSE: AIM) has announced the IRB approval to commence its Phase 2 clinical trial for Ampligen in treating locally advanced pancreatic cancer (LAPC). The trial, AMP-270, aims to evaluate the efficacy of Ampligen against a no-treatment control group following FOLFIRINOX chemotherapy. Approximately 90 subjects will be enrolled across 30 centers in the U.S. and Europe. Initial data from a small cohort showed promising survival rates, with two patients surviving 34 and 43 months, and one patient alive at 54 months. The trial is expected to start patient recruitment by Q4 2022.

AIM ImmunoTech Inc., an immuno-pharma company focused on therapies for cancers and viral diseases, announced that the Delaware Court of Chancery denied an activist shareholder's temporary restraining order aimed at influencing the Board's composition. Jonathan Jorgl sought to nominate candidates for the Board at the 2022 Annual Meeting, but the Court's decision means that AIM can proceed without disruption. A preliminary injunction hearing is scheduled for October 5, 2022. The Company continues its commitment to protect shareholder rights.

AIM ImmunoTech Inc. (NYSE: AIM) reported its Q2 2022 financial results, revealing a cash position of $34.5 million, up from $32.1 million at the end of 2021. Positive developments include upcoming Phase 2 studies for Ampligen in pancreatic cancer and favorable data from trials targeting advanced ovarian and colorectal cancers. The company anticipates reaching key clinical and regulatory milestones and expects to maintain sufficient capital through 2023. Despite industry challenges, AIM remains focused on advancing Ampligen's therapeutic potential.

AIM ImmunoTech Inc. (AIM) announced positive preliminary data from its Expanded Access Program for Ampligen, an investigational drug for treating Post-COVID conditions. The results indicated significant improvements in chronic fatigue among patients receiving Ampligen. Based on these findings, AIM plans to file an Investigational New Drug (IND) application with the FDA for a Phase 2 study of Ampligen targeting long COVID. The drug is being developed for various conditions, including cancers and immune disorders.

AIM ImmunoTech reported promising results for Ampligen® (rintatolimod) in treating metastatic and locally advanced pancreatic cancer. Data presented by Professor C.H.J. van Eijck at the 5th Dutch Multidisciplinary Gastrointestinal Oncology Congress indicated improved survival rates for patients undergoing this maintenance therapy post-chemotherapy with FOLFIRINOX. The company plans to advance Ampligen into a Phase 2 clinical study (AMP-270) aimed at evaluating its efficacy in patients with locally advanced pancreatic cancer, enrolling around 90 subjects across the U.S. and Europe.

AIM ImmunoTech Inc. has filed a complaint in federal court against an activist group led by Jonathan Jorgl, seeking to prevent a potential hostile takeover and address violations of securities laws. The AIM Board unanimously rejected Jorgl's nomination notice due to significant deficiencies, including false statements. AIM emphasizes its commitment to protecting stockholders and achieving financial stability, with ~$44.5 million in liquid assets and ongoing oncology clinical trials showing promising interim results. AIM reassures stockholders that no immediate action is required.

AIM ImmunoTech will host a live video webcast on July 25, 2022, at 8:30 AM ET, featuring a moderated roundtable with key opinion leader Professor C.H.J. van Eijck from Erasmus Medical Center.

The event will cover the company's lead asset, Ampligen (rintatolimod), focusing on its clinical development for pancreatic cancer.

Investors can submit questions during the session. A recording will be available on the company’s website after the event.

AIM ImmunoTech Inc. has signed a lease for a 5,210 square foot R&D facility at the New Jersey Bioscience Center, a leading incubator focused on life sciences. This move aims to enhance the research and development of Ampligen, their lead product targeting cancers and viral diseases, including COVID-19. The New Jersey Economic Development Authority supports the initiative, underlining AIM's commitment to advancing therapeutics. The NJBC has invested over $70 million into its facilities to support life science innovations.